British pharmaceutical company GSK said on Wednesday that it has agreed to pay $2.3 billion to put an end to lawsuits in the United States alleging that its heartburn drug Zantac caused cancer.

British pharmaceutical company GSK said on Wednesday that it has agreed to pay $2.3 billion to put an end to lawsuits in the United States alleging that its heartburn drug Zantac caused cancer. "GSK today announced that it has reached agreements with 10 plaintiff firms who together represent 93 per cent (approximately 80,000) of the Zantac state court product liability cases pending against GSK," the company said in a statement. Under the agreement, whose terms are confidential, GSK will make an "aggregate payment of up to $2.2 billion" to resolve these cases, the statement added. The company also said on Wednesday that it had reached another agreement in principle to pay $70 million to settle a separate Zantac case with US laboratory Valisure -- which is still subject to final approval by the US Department of Justice. Also Read | ‘It needs to go’: Tim Walz calls for scrapping of electoral college system Class action and personal injury lawsuits have been filed in US courts after the Food and Drug Administration warned in 2019 that some ranitidine drugs, including Zantac, contained low levels of an environmental contaminant considered a probable carcinogen. However the pharmaceutical giant said it "has not admitted any liability" by settling the case as "the scientific consensus remains that there is no consistent or reliable evidence" that ranitidine is carcinogenic. Also Read | ‘Your behaviour not unnoticed,’ Philippines embarrasses China at ASEAN summit The over-the-counter treatment, known also by its non-commercial name ranitidine, was manufactured by several rivals, including the French group Sanofi and US drugmaker Pfizer, before it was withdrawn in 2019. In recent years, GSK has won several court cases on the issue in the United States, while signing several other settlements to avoid litigation. Disclaimer: This story has been published from a news agency feed with minimal edits to adhere to WION's style guide. The headline may have been changed to better reflect the content of the story or to make it more suitable for WION audience.

Pharma company GSK agrees to pay $2.3bn in US settlements on lawsuits over Zantac cancer claims

lawsuit-against-gsk

Lawsuit Against Gsk, News on Lawsuit Against Gsk, stories on Lawsuit Against Gsk, articles on Lawsuit Against Gsk, Lawsuit Against Gsk stories at Wion, Lawsuit Against Gsk news, Lawsuit Against Gsk latest news

lawsuit against-gsk

Pharma company GSK agrees to pay $2.3bn in US settlements on lawsuits over Zantac cancer claims